Research

The research
behind LionBio

We're developing a nasal formulation of semaglutide in a biodegradable polymer nanoparticle. Academic animal studies informed the approach. Our current work focuses on drug distribution, release, and preparation for clinical studies.

Stage: preclinical development

Where we started

LionBio's approach grew out of academic studies of nasal peptide delivery and the biology of the olfactory bulb.

The olfactory lining in the upper nose connects to this brain region through the olfactory nerves. The bulb processes information about smell and communicates with circuits involved in feeding and metabolism.4 In mice, it also contains cells that produce GLP-1 and cells that respond to it. A published study found that activating GLP-1 receptors here increased insulin release in response to glucose.5

This biology gives us a reason to investigate nasal peptide delivery. The academic work behind LionBio examined how formulation and delivery route affected drug-label distribution, body weight and retching in animals.1

Brain Olfactory bulb a brain region involved in smell Blood-brain barrier Bloodstream Olfactory epithelium, top of the nose Proposed route
Proposed route for nasal peptide delivery. Brain delivery remains under investigation. Schematic, not to scale.

Why the nanoparticle matters

Researchers compared free tirzepatide with tirzepatide encapsulated in biodegradable nanoparticles, both delivered through the nose. Male mice with diet-induced obesity received the same dose of drug each day for eight days.1

Body weight fell more in the nanoparticle group, while free nasal tirzepatide produced little change under the same conditions. The comparison supports a role for formulation in the observed response, though it does not establish where the active drug acted.1

Mean body-weight change over eight days of daily nasal tirzepatide in male mice with diet-induced obesity. The nanoparticle group lost more weight than the free-drug or vehicle groups. Variability is not shown.
Body-weight change from each group's starting weight. Nanoparticle: n = 7; free drug: n = 8; vehicle: n = 7. Group means shown; variability is not displayed. Unpublished academic research, not peer reviewed.1

Weight change in mice

In a separate four-week study, researchers tracked mice receiving daily nasal tirzepatide nanoparticles, injected tirzepatide or vehicle. Average body weight in the nasal group fell by 26.7% from its starting level. Both drug groups also showed reductions in fat mass.1

Nasal particleInjectedVehicle +0%-10%-20%-30% 07142127DAY Vehicle −11% Nasal particle −27% Injected −33%
Mean body-weight change from each group's starting weight in male mice with diet-induced obesity. Nasal: n = 8; injected: n = 7; vehicle: n = 8. Routes were studied at different doses. Group means shown. Unpublished academic research, not peer reviewed.1

Semaglutide

The same academic research also tested nasal semaglutide nanoparticles. Over six days, body weight fell in the treated group while vehicle controls remained close to their starting weight. The experiment included seven treated mice and six vehicle controls.1

LionBio's current semaglutide research builds on these academic experiments with studies of drug exposure and biological response.

Distribution and tolerability

Tracing distribution

Researchers detected a fluorescent label in the olfactory bulb one hour after nasal dosing of labelled tirzepatide nanoparticles in mice. The images below show one representative animal from each group.1

The experiment tracks the label. Measuring how much intact drug reaches the tissue requires a different assay, and remains a question for further study.

VehicleNasal particleInjected
1 h Fluorescence image of a mouse brain one hour after vehicle Fluorescence image of a mouse brain one hour after a nasal dose of labelled tirzepatide nanoparticles Fluorescence image of a mouse brain one hour after an injected dose of labelled tirzepatide
One hour after a single dose: vehicle, nasal nanoparticles and injected tirzepatide. Different doses were used between routes. Representative mouse images; fluorescence does not quantify intact drug. Unpublished academic research, not peer reviewed.1

Retching in minks

In an exploratory single-dose study, female minks receiving nasal semaglutide nanoparticles had fewer retching episodes than those receiving injected semaglutide during a two-hour observation period.123

Routes were studied at different doses. This observation does not establish an overall tolerability advantage.

Unpublished animal research, not peer reviewed. Results may not translate to people.

Where we are, and where we're going

  1. Complete · 2024

    Academic studies

    Initial animal studies informed the formulation and delivery approach.

  2. Underway · Q3 2026

    Rat studies

    Measuring semaglutide in blood and brain after nasal dosing.

  3. Planned · Q1 2027

    Non-human primate studies

    Studying nasal delivery and drug exposure in non-human primates.

  4. In progress · Q4 2026

    Formulation and manufacturing

    Developing a consistent formulation and a process for larger batches.

  5. Target: Q4 2027

    First clinical study

    Preparing to test the formulation in people.

The clinical timeline depends on preclinical results, manufacturing readiness, and the required regulatory and ethics approvals.

LionBio's nasal formulation is investigational. Its safety and effectiveness in people have not been established, and it is not approved for human use.

Research from the Leong lab

Our nanoparticle approach came out of Kam Leong's lab at Columbia University, which has spent decades on drug and gene delivery, nonviral gene editing, scalable nanoparticle manufacturing and biomaterials. A selection of the lab's papers, by area.

Drug and gene delivery +
Nonviral gene editing +
Nanotherapeutics manufacturing +
Biomaterials for regenerative medicine +
Sources
  1. Wan Q, Li Z, Ding S, Shi M-Y, et al. GLP-1 drug targets the olfactory bulb to combat obesity. Manuscript in preparation (Peking University, Columbia University, University of Science and Technology of China). Unpublished academic study, not peer reviewed; animal data summarised here.
  2. Horn CC, et al. Why can't rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS One 2013;8:e60537. PubMed
  3. Zhang F, et al. Value of mink vomit model in study of anti-emetic drugs. World J Gastroenterol 2006;12:1300-1302. PubMed
  4. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-628. PubMed
  5. Montaner M, Denom J, Simon V, et al. A neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretion. Nat Commun 2024;15:6941. DOI

Questions about the research?

Updates

Follow our progress

Research updates and news from the team.

For research, partnerships or investor inquiries: hello@lion.bio

Company updates only. Unsubscribe at any time.